Andere talen Quoin Pharmaceuticals, Ltd.

Aandelen

QNRX

US74907L3006

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,6321 ^USD	-4,23%		-13,78%	-87,11%

15/03	QUOIN PHARMACEUTICALS, LTD. : Maxim herhaalt koopadvies	ZM
14/03	Quoin Pharmaceuticals zoekt mogelijkheden voor fusies en overnames	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Quoin Pharmaceuticals Seeks M&A Opportunities	14/03
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	13/03
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results	13/03
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET	07/03
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	06/03
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	05/03
Top Midday Decliners	05/03
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall	05/03
Top Premarket Decliners	05/03
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering	05/03
Top Midday Gainers	04/03
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	04/03
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04/03
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04/03
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome	15/02
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08/02
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08/02
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP	25/01
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	18/12
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Quoin Pharmaceuticals, Ltd.

Aandelen

QNRX

US74907L3006

Andere talen

Filters